Relationship between oligomer and functional serum mannose-binding lectin in chronic renal failure. 2010

Atsushi Satomura, and Takayuki Fujita, and Yoshinobu Fuke, and Mitsuru Yanai, and Kazunari Kumasaka, and Eiichi Takayama, and Hiroaki Hamada, and Toshiharu Maruyama, and Tomohiro Nakayama
Division of Laboratory Medicine, Department of Pathology and Microbiology, Nihon University School of Medicine, Itabashi, Tokyo, Japan. atsushis@med.nihon-u.ac.jp

BACKGROUND Mannose-binding lectin (MBL) plays an important role in first-line host defence against pathogens via the lectin pathway. The binding affinity for ligands is greatly increased by oligomerization, although the basic triplet does not bind solid phase mannan and cannot activate complement. Besides, MBL is a positive acute-phase protein. In this study, we examined the relationship between oligomer and functional serum MBL in chronic renal failure patients who were either uraemic [Pre-haemodialysis (pre-HD) patients], or who were receiving maintenance haemodialysis treatment (HD patients). METHODS This study included a total of 20 Pre-HD patients, 130 HD patients and 28 healthy subjects. The oligomer and functional serum MBL levels were measured using enzyme-linked immunosorbent assays established previously. RESULTS The median serum functional MBL levels were significantly reduced in both Pre-HD and HD patients compared with healthy subjects (P<0·05 for both). Furthermore, the median functional MBL level in Pre-HD patients was significantly lower than that in HD patients (P<0·05). The median serum oligomer MBL levels in both Pre-HD and HD patients were significantly higher compared with healthy subjects (P<0·05 for both). Furthermore, the median oligomer MBL level in HD patients was significantly (P<0·05) higher than that in Pre-HD patients. The ratios of median serum functional MBL levels to oligomer MBL levels were significantly reduced in both Pre-HD and HD patients compared with healthy subjects (P<0·05 for both). CONCLUSIONS We found significant reductions in the ratios of serum functional MBL levels to oligomer MBL levels in HD and Pre-HD patients compared with healthy subjects.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002097 C-Reactive Protein A plasma protein that circulates in increased amounts during inflammation and after tissue damage. C-Reactive Protein measured by more sensitive methods often for coronary heart disease risk assessment is referred to as High Sensitivity C-Reactive Protein (hs-CRP). High Sensitivity C-Reactive Protein,hs-CRP,hsCRP,C Reactive Protein,High Sensitivity C Reactive Protein
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005260 Female Females
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Atsushi Satomura, and Takayuki Fujita, and Yoshinobu Fuke, and Mitsuru Yanai, and Kazunari Kumasaka, and Eiichi Takayama, and Hiroaki Hamada, and Toshiharu Maruyama, and Tomohiro Nakayama
February 2014, Neurochemical research,
Atsushi Satomura, and Takayuki Fujita, and Yoshinobu Fuke, and Mitsuru Yanai, and Kazunari Kumasaka, and Eiichi Takayama, and Hiroaki Hamada, and Toshiharu Maruyama, and Tomohiro Nakayama
January 2009, Clinical and experimental rheumatology,
Atsushi Satomura, and Takayuki Fujita, and Yoshinobu Fuke, and Mitsuru Yanai, and Kazunari Kumasaka, and Eiichi Takayama, and Hiroaki Hamada, and Toshiharu Maruyama, and Tomohiro Nakayama
July 2013, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology,
Atsushi Satomura, and Takayuki Fujita, and Yoshinobu Fuke, and Mitsuru Yanai, and Kazunari Kumasaka, and Eiichi Takayama, and Hiroaki Hamada, and Toshiharu Maruyama, and Tomohiro Nakayama
January 2017, The Egyptian journal of immunology,
Atsushi Satomura, and Takayuki Fujita, and Yoshinobu Fuke, and Mitsuru Yanai, and Kazunari Kumasaka, and Eiichi Takayama, and Hiroaki Hamada, and Toshiharu Maruyama, and Tomohiro Nakayama
March 2023, European review for medical and pharmacological sciences,
Atsushi Satomura, and Takayuki Fujita, and Yoshinobu Fuke, and Mitsuru Yanai, and Kazunari Kumasaka, and Eiichi Takayama, and Hiroaki Hamada, and Toshiharu Maruyama, and Tomohiro Nakayama
January 2008, Clinical and experimental obstetrics & gynecology,
Atsushi Satomura, and Takayuki Fujita, and Yoshinobu Fuke, and Mitsuru Yanai, and Kazunari Kumasaka, and Eiichi Takayama, and Hiroaki Hamada, and Toshiharu Maruyama, and Tomohiro Nakayama
June 2011, Microbiology and immunology,
Atsushi Satomura, and Takayuki Fujita, and Yoshinobu Fuke, and Mitsuru Yanai, and Kazunari Kumasaka, and Eiichi Takayama, and Hiroaki Hamada, and Toshiharu Maruyama, and Tomohiro Nakayama
December 2019, The American journal of tropical medicine and hygiene,
Atsushi Satomura, and Takayuki Fujita, and Yoshinobu Fuke, and Mitsuru Yanai, and Kazunari Kumasaka, and Eiichi Takayama, and Hiroaki Hamada, and Toshiharu Maruyama, and Tomohiro Nakayama
January 2002, Lancet (London, England),
Atsushi Satomura, and Takayuki Fujita, and Yoshinobu Fuke, and Mitsuru Yanai, and Kazunari Kumasaka, and Eiichi Takayama, and Hiroaki Hamada, and Toshiharu Maruyama, and Tomohiro Nakayama
January 2002, Lancet (London, England),
Copied contents to your clipboard!